SCHEMBL5282396

SCHEMBL5282396

COc1cc2nncc(N3CCc4ccccc43)c2cc1OC

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 3/20 0.61
CSF1R P07333 1/20 0.60
KIT P10721 2/20 0.53
PDE10A Q9Y233 5/20 0.49
PDGFRB P09619 1/20 0.46
KDM4E B2RXH2 3/20 0.44
ALDH1A1 P00352 3/20 0.44
POLB P06746 2/20 0.44
PDE4A P27815 1/20 0.41
PDE4B Q07343 1/20 0.41
PDE4C Q08493 1/20 0.41
PDE4D Q08499 1/20 0.41
RET P07949 1/20 0.41
KIF5B P33176 1/20 0.41
KDR P35968 1/20 0.41
GSK3A P49840 1/20 0.41
GSK3B P49841 1/20 0.41
MEN1 O00255 1/20 0.41
JAK2 O60674 1/20 0.41
TSHR P16473 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5247955 0.93 KIT (0.54) EGFRCSF1RKITPDE10APDGFRB
SCHEMBL5247296 0.86 PDE10A (0.44) EGFRCSF1RKITPDE10APDGFRB
SCHEMBL5244024 0.86 EGFR (0.45) EGFRCSF1RKITPDE10APDGFRB
SCHEMBL5290250 0.85 EGFR (0.44) EGFRCSF1RKITPDE10APDGFRB
SCHEMBL5288680 0.82 PDE10A (0.53) EGFRCSF1RKITPDE10APDGFRB
SCHEMBL4774642 0.81 EGFR (0.43) EGFRCSF1RKITPDE10APDGFRB
SCHEMBL4778978 0.81 PDE10A (0.42) EGFRCSF1RKITPDE10APDGFRB
SCHEMBL4772378 0.81 ROCK1 (0.46) EGFRCSF1RPDE10APDGFRBSMN1; SMN2
SCHEMBL5245531 0.80 ALDH1A1 (0.47) EGFRCSF1RPDE10APDGFRBALDH1A1
SCHEMBL5243650 0.80 ROCK1 (0.45) EGFRCSF1RPDE10APDGFRBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160814-A1 Phosphodiesterase 10 inhibitors MEMORY PHARMACEUTICALS CORPORATION 2006-07-20 US claimed
EP-1802585-A1 4-SUBSTITUTED 4,6-DIALKOXY-CINNOLINE DERIVATIVES AS PHOSPODIESTERASE 10 INHIBITORS FOR THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL SYNDROMS Memory Pharmaceuticals Corporation (US) 2007-07-04 EP disclosed
US-20060160814-A1 Phosphodiesterase 10 inhibitors MEMORY PHARMACEUTICALS CORPORATION 2006-07-20 US disclosed
WO-2006028957-A1 4-SUBSTITUTED 4, 6-DIALKOXY-CINNOLINE DERIVATIVES AS PHOSPODIESTERASE 10 INHIBITORS FOR THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL SYNDROMS MEMORY PHARMACEUTICALS CORPORATION (US) 2006-03-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160814-A1 Phosphodiesterase 10 inhibitors PDE5A, PDE3A, PDE2A EGFR 4662/4885CSF1R 4089/4885KIT 2080/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.